TABATHA GRACE: Open Payments
NPI 1104402338 · SHOW LOW, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 44 payments from 11 companies in 2025. Trend: 2023 $171 · 2024 $490 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $231 |
| Neurocrine BioSciences, Inc. | 8 | $175 |
| Janssen Pharmaceuticals, Inc | 4 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| GlaxoSmithKline, LLC. | 3 | $60 |
| Alkermes, Inc. | 2 | $58 |
| Exact Sciences Corporation | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Lilly USA, LLC | 1 | $15 |
Products named: INGREZZA, AUSTEDO XR, ABILIFY MAINTENA, SPRAVATO, FANAPT, UZEDY, TRELEGY ELLIPTA, LYBALVI.
Industry payments across AZ — which companies pay providers there.
